Patents by Inventor Ugra Sen Singh

Ugra Sen Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METFORMIN IN TREATMENT OF NEUROBLASTOMA
    Publication number: 20170049726
    Abstract: Use of metformin in inhibition of growth and/or viability of human neuroblastoma cells is described. Use of metformin in inhibition of growth and/or viability of neuroblastoma cancer stem cells is also described. The metformin is shown to be effective both in vitro and in vivo in inhibition of growth and/or viability of neuroblastoma cells of multiple different genetic backgrounds.
    Type: Application
    Filed: August 22, 2016
    Publication date: February 23, 2017
    Inventors: Ambrish Kumar, Ugra Sen Singh, Donald J. Dipette
  • Sparstolonin B based pharmaceutical agent for neuroblastoma treatment
    Patent number: 9446019
    Abstract: Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb Sparganium stoloniferum or can be synthetic. The sparstolonin B is shown to be effective both in vitro and in vivo in inhibition of growth and/or viability of neuroblastoma cells of multiple different genetic backgrounds including N-myc amplified with wild p53 neuroblastoma cells, N-myc amplified with mutated p53 neuroblastoma cells, and N-myc nonamplified neuroblastoma cells.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: September 20, 2016
    Assignee: University of South Carolina
    Inventors: Ambrish Kumar, Ugra Sen Singh, Daping Fan, Donald J. Dipette
  • Sparstolonin B Based Pharmaceutical Agent for Neuroblastoma Treatment
    Publication number: 20150105454
    Abstract: Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb Sparganium stoloniferum or can be synthetic. The sparstolonin B is shown to be effective both in vitro and in vivo in inhibition of growth and/or viability of neuroblastoma cells of multiple different genetic backgrounds including N-myc amplified with wild p53 neuroblastoma cells, N-myc amplified with mutated p53 neuroblastoma cells, and N-myc nonamplified neuroblastoma cells.
    Type: Application
    Filed: September 11, 2014
    Publication date: April 16, 2015
    Inventors: Ambrish Kumar, Ugra Sen Singh, Daping Fan, Donald J. Dipette